Cosimi A Benedict, Sachs David H
Transplantation Unit of the General Surgical Service, and the Transplantation Biology Research Center, Massachusetts General Hospital, and the Department of Surgery, Harvard Medical School, Boston, USA.
Transplantation. 2004 Mar 27;77(6):943-6. doi: 10.1097/01.tp.0000117779.23431.3f.
Establishment of mixed hematopoietic chimerism carries with it the induction of transplantation tolerance to any other tissue or organ from the same donor. This strategy has been studied extensively for induction of tolerance in mice. During the past decade, we have extended the same strategy, with modifications, to cynomolgus monkeys and most recently to renal transplant patients. In this report we review the evolution of these studies from preclinical applications to our current clinical experience with two therapeutic protocols sponsored by the Immune Tolerance Network. The first of these studies is for patients with myeloma and end-stage renal disease with an HLA-matched sibling donor; the second for patients with end-stage renal disease and HLA-mismatched donors. Although it is still early in the course of these studies, the results to date are very encouraging.
建立混合造血嵌合体伴随着对来自同一供体的任何其他组织或器官的移植耐受诱导。该策略已在小鼠中广泛研究用于诱导耐受。在过去十年中，我们对该策略进行了改进并将其扩展到食蟹猴，最近又扩展到肾移植患者。在本报告中，我们回顾了这些研究从临床前应用到我们目前在免疫耐受网络赞助的两个治疗方案中的临床经验的演变。这些研究中的第一项是针对患有骨髓瘤和终末期肾病且有 HLA 匹配同胞供体的患者；第二项是针对患有终末期肾病且供体 HLA 不匹配的患者。尽管这些研究仍处于早期阶段，但迄今为止的结果非常令人鼓舞。
